ArticleFrontiers in cell and developmental biology2026
Decoding coronary artery calcification: metabolic reprogramming features and a promising circulating biomarker PXDN.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery calcification (CAC) is a strong predictor of cardiovascular disease, yet metabolism-related molecular alterations underlying CAC remain poorly understood. This study aimed to explore metabolism-related transcriptional changes associated with CAC and identify potential circulating biomarkers for early detection and risk stratification. Methods: Two transcriptomic datasets, GSE58150 (discovery cohort) and GSE211752 (validation cohort), were analyzed after excluding poor-quality samples. Differential expression, gene set enrichment analysis (GSEA), and metabolic feature identification were performed. Weighted gene co-expression network analysis (WGCNA) identified CAC-related gene modules, whose functions were explored by GSEA. Differentially expressed genes were further evaluated via protein-protein interaction networks and LASSO regression to screen biomarker candidates. Diagnostic value was assessed by ROC curves, and regulatory networks of transcription factors and miRNAs were constructed. A CAC mouse model was then established, with qRT-PCR, Western blotting, and immunohistochemistry used to validate biomarker expression. Results: The discovery cohort included 8 CAC and eight controls; the validation cohort comprised 6 CAC and six controls. A total of 138 genes were upregulated and 104 downregulated in CAC. Functional enrichment indicated alterations in amino acid and vitamin metabolism. WGCNA highlighted the ME2 module as strongly correlated with CAC. GSEA revealed activation of immune-related pathways and suppression of metabolic pathways. LASSO regression identified five biomarker candidates: NRG1, PXDN, ACTL7A, ACSS3, and SHANK3. Among them, PXDN showed the strongest diagnostic performance (AUC 0.95 and 0.83 in discovery and validation cohorts, respectively) and higher expression associated with increased CAC risk. Regulatory analysis suggested PXDN may be modulated by multiple transcription factors and miRNAs. Conclusion: CAC is associated with transcriptional alterations in metabolism-related pathways. PXDN was identified as a potential circulating biomarker for CAC, providing a basis for future mechanistic studies and non-invasive risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.